OpenAI acquires Orchestra Bio to expand its biotech business
🎧 Listen to this story
OpenAI announced on its website that it acquired Orchestra Bio, a four-year-old biotech software startup. The terms were not disclosed; according to TechCrunch, the company had reportedly raised around $20 million by 2025 from backers including Andreessen Horowitz, Atria, and 8VC.
Orchestra develops AI agents to help biotech companies manage drug discovery operations, including financial tracking and scheduling issues for clinical trials. OpenAI says it will add the team and technology to Rosalind, its AI model for life sciences research, and to Rosalind Workbench, a tool designed to help researchers plan experiments and analyze results. OpenAI says Moderna and Novo Nordisk are among Rosalind’s customers.
Why it matters · editorial interpretation
The acquisition could broaden Rosalind’s scope by combining agents for drug-discovery operations with tools for experiment planning and result analysis. Because the terms were not disclosed, the deal’s strategic or financial value cannot yet be assessed; OpenAI says Moderna and Novo Nordisk are among Rosalind’s customers.
Sources
Business